Table: Bitter Medicine
Embarrassed by a number of drug manufacturing snafus, these pharmaceutical and biotech companies are scrambling to clean up their acts.
CO. & DRUG NAME PROGNOSIS
SCHERING-PLOUGH Some Proventil inhalers were shipped with- Proventil out the active ingredient, and 59 million (asthma), were subject to recall. Schering is spend- Clarinex ing more than $50 million to correct (allergies) its manufacturing deficiencies.
ELI LILLY In March, the FDA said it won't approve Zyprexa these new drugs until Lilly improves (schizophrenia) quality control and other processes. The Forteo company says both drugs will launch by (osteoporosis) yearend: Forteo on schedule, but Zyprexa will have been delayed by six months.
IMMUNEX Sales zoomed to $650 million in two years, Enbrel but Immunex didn't have enough (rheumatoid manufacturing capacity to meet demand. arthritis) With 80,000 patients waiting for the drug, Immunex will lose out on an estimated $200 million in sales this year.
Data: Company Reports